<DOC>
	<DOCNO>NCT02535299</DOCNO>
	<brief_summary>Objectives : To investigate treatment effect insulin , metformin Liraglutide ; Type 2 Diabetes hospital , order investigate possible mechanism telomere-telomerase system Par-4 .</brief_summary>
	<brief_title>Par-4 Telomere-telomerase System Type 2 Diabetes Patients Who Received GLP-1 Metformin Treatment</brief_title>
	<detailed_description>160 Type 2 diabetes hospital divide 4 group : group A ( 40 healthy volunteer ) , group B ( 40 patient give basal insulin treatment , group C（40 patient give basal Liraglutide treatment ) , group D（40 patient give basal metformin treatment ) . The age , height , weight , blood glucose , glycosylated hemoglobin A1c（HbA1c） , homeostasis model assessment ( HOMA-IR ) , lipid , blood pressure , course disease , telomere length , telomerase activity record respectively . And High-sensitive C-reactive protein ( HsCRP ) , Par-4 , GST , SOD , GSH-PX , ATF-6 , CHOP , XBP-1 Tumor necrosis factor-α（TNF-α） detect Baseline . After group 's treatment , Change baseline index record , Multifactor logistic regression analyze correlation positive index .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Newly dignosised type 2 diabetes accord WHO criteria.glycated hemoglobin ( HbA1c ) 10 % ; Seronegative antibody insulin , islet cell glutamic acid decarboxylase ( GAD ) ; Type 1 diabetes mellitus , presence autoimmune diabetes indicate antibody insulin , islet cell , GAD； Gestational diabetes ; patient heart , liver , renal function impairment ; presence severe infection cerebrovascular disease ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>telomere-telomerase</keyword>
	<keyword>Par-4</keyword>
	<keyword>GLP-1</keyword>
	<keyword>metformin</keyword>
</DOC>